Alexander Ashall-Kelly

Title: Alexander Ashall-Kelly: Innovator in Pharmaceutical Chemistry

Introduction

Alexander Ashall-Kelly is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target the CFTR channel. With a total of two patents to his name, Ashall-Kelly's work is recognized for its potential therapeutic applications.

Latest Patents

Ashall-Kelly's latest patents include innovative compounds designed for inhibiting the CFTR channel. The first patent presents a compound of formula I or a pharmaceutically acceptable salt thereof, along with its therapeutic uses. Additionally, it provides a combination of pharmacologically active agents and a pharmaceutical composition. The second patent focuses on substituted pyrazino[1',2':1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4',5':3,4]pyrrolo[2,1-c][1,4]oxazines, and pyrimido[4',5':3,4]pyrrolo[1,2-d][1,4]oxazepines, also aimed at inhibiting the CFTR channel, along with their therapeutic uses and combinations.

Career Highlights

Ashall-Kelly is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions in drug development, contributing to advancements in medical science.

Collaborations

Ashall-Kelly has collaborated with notable colleagues, including Mahbub Ahmed and Louisa Gueritz. These collaborations have fostered a productive environment for research and innovation in pharmaceutical chemistry.

Conclusion

Alexander Ashall-Kelly is a distinguished inventor whose work in pharmaceutical chemistry has the potential to impact therapeutic practices significantly. His contributions through patents and collaborations highlight his commitment to advancing medical science.